The $90,000 boost from angel investors is the first outside capital for the company with a diagnostic test for Alzheimer's disease.
"Imagine all diagnostics some day being reduced to a simple blood test," said CEO Roopam Banerjee, who believes Raindance products are a "step in that direction."
The goal for the multiyear partnership is to make genetic analysis a routine part of patient care.
Today, the storied venture firm funded Spiral Medicine, a company that processes genetic information for the purposes of clinical medicine and research.
Editor's Pick Futurist and entrepreneur Michael Vassar has a bone to pick with the U.S. medical system. He hopes to "humiliate" it into providing better quality care by creating a "product that works better than the system."
Guest Post Genomics data is about to change the way doctors discover and treat disease -- but there are some significant obstacles standing in the way.
Guest Post Companies all over the world are becoming increasingly worried about their ability to innovate and compete in the fast-changing technology world. That’s according to GE’s third annual “Global Innovation Barometer” released Jan 17.
The cost of sequencing the human genome has plummeted. But how will this benefit doctors and patients?
The startups that have been selected for the first class are far from sexy -- unless a "software-defined infrastructure platform for heterogeneous computing" does it for you -- but they're all generating revenues. What they have in common is that they target their products at businesses, not consumers.
Editor's Pick Ayasdi is working with the nation's top hospitals and medical researchers to uncover more targeted treatments for disease.
Guest Post Attempts to regulate or restrict the export of American biotechnology are likely to backfire and hurt American competitiveness.
At CloudBeat, the healthcare panel kicked off with a harrowing statistic. The vast majority of breast cancer sufferers will not benefit from chemotherapy. And yet, most patients today receive this highly invasive treatment.
According to genetics expert Ken Stineman, over …
Is there more to your bacteria then meets the eye?
A new cancer discovery puts the emerging field of genomics on the map, may speed up the drug approval process, and de-risks groundbreaking research for venture-funded biotech companies.
BioNanomatrix, a Philadelphia developer of genome-analysis systems, raised $5.1 million in a first funding round. Investors included Battelle Ventures, Innovation Valley Partners, KT Venture Group, Ben Franklin Technology Partners and21Ventures.
BioNanomatrix is developing a single-molecule imaging and analysis system that …
Mohr Davidow Ventures partner Bill Ericson, who helped fund high-speed genome-sequencer Pacific Biosciences, is a big believer in the emerging Age of Genomics and its potential to transform medicine, health insurance and our understanding of ourselves.
Check out my recent …
Bill Ericson doesn’t see much cause for pessimism about the dawning Genomic Age. The Mohr Davidow Ventures partner, who’s helped resuscitate the firm’s life-science practice since he came aboard in 2000, believes the widespread dissemination of genetic information will be …
(UPDATED: Expanded items on LineaGen, BG Medicine. Pelikan Tech is described in a standalone item here.)
Pelikan Tech raises $69M for diabetes glucose tests (release)
Utah’s LineaGen draws $6M for genetic diagnostics (VentureWire, sub req’d)
Featured companies: Mawell, OpGen, Vital Therapeutics
Optical genome-mapper OpGen raises $23.6M in a restart — OpGen, a Madison, Wisc., biotech developing a genomic test for identifying disease-causing microbes, raised $23.6 million in what the company is billing as a first …
(UPDATED: See below.)
For some reason, biotechnology is rife with chameleons — companies that suddenly and radically alter their scientific strategy, disease focus or business model, sometimes to recover from a major failure, and sometimes just to be whatever …